Key result
The CYP2C19*3 allele was significantly associated with clopidogrel high on treatment reactivity in ischemic heart disease patients, with 14.3% of the overall cohort identified as nonresponders.
Why the study?
Polymorphisms in CYP2C19 and PON-1 genes are thought to be involved in clopidogrel high on treatment reactivity in patients with ischemic heart disease.
Do CYP2C19 and PON-1 polymorphisms predict clopidogrel high on treatment reactivity in patients with ischemic heart disease?
Observational (n=240)
Do CYP2C19 and PON-1 polymorphisms predict clopidogrel high on treatment reactivity in patients with ischemic heart disease?
The CYP2C19*3 loss-of-function allele is significantly associated with clopidogrel resistance in Punjabi Pakistani patients with ischemic heart disease.
Aim: Polymorphisms in cytochrome P450 (CYP) 2C19 and paraoxonase-1 (PON-1) genes are thought to be involved in clopidogrel high on treatment reactivity in ischemic heart disease (IHD) patients. Methods: A total of 240 patients with IHD were screened for CYP2C19 loss-of-function alleles (LOF; *2, *3) and PON-1 Q192R. Patients were classified as responders and nonresponders to clopidogrel based upon platelet aggregation studies. Genotyping of the CYP2C19 and PON-1 allele was carried out by PCR-RFLP. Results: Results showed that 14.3% of the patients were nonresponders, whereas 85.7% were responders to the clopidogrel therapy. CYP2C19*3 allele showed significant association with clopidogrel high on treatment reactivity in IHD patients. Conclusion: Result of our study demonstrate that IHD patients with CYP2C19*3 allele can face the problem of clopidogrel high on treatment reactivity in Punjabi Pakistani population.
No takes yet. Share an insight, caveat, or question.
Akram et al. (2019) conducted an observational in Ischemic Heart Disease (n=240). CYP2C19 and PON-1 polymorphisms vs. Patients without the polymorphisms was evaluated on Clopidogrel high on treatment reactivity (nonresponder status). The CYP2C19*3 allele was significantly associated with clopidogrel high on treatment reactivity in ischemic heart disease patients, with 14.3% of the overall cohort identified as nonresponders.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: